These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 8600545

  • 1. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma.
    Fay JW, Bernstein SH.
    Semin Oncol; 1996 Apr; 23(2 Suppl 4):22-7. PubMed ID: 8600545
    [Abstract] [Full Text] [Related]

  • 2. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study.
    Fay JW, Lazarus H, Herzig R, Saez R, Stevens DA, Collins RH, Piñeiro LA, Cooper BW, DiCesare J, Campion M.
    Blood; 1994 Oct 01; 84(7):2151-7. PubMed ID: 7919329
    [Abstract] [Full Text] [Related]

  • 3. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM, Fortuna A, Fogli M, Gherlinzoni F, Rosti G, Catani L, Gozzetti A, Miggiano MC, Tura S.
    Exp Hematol; 1995 Dec 01; 23(14):1520-6. PubMed ID: 8542941
    [Abstract] [Full Text] [Related]

  • 4. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM, Bierman PJ, Ruby E, Reed EC, Bishop MR, Tarantolo S, Kessinger A, Armitage JO.
    Bone Marrow Transplant; 1996 Jun 01; 17(6):951-6. PubMed ID: 8807099
    [Abstract] [Full Text] [Related]

  • 5. Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.
    Colombat P, Delain M, Desbois I, Domenech J, Binet C, Tabah I, Lamagnere JP, Linassier C.
    Bone Marrow Transplant; 1996 Aug 01; 18(2):293-9. PubMed ID: 8864437
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M, Couture F, Kovacs M, Saragosa R, McCrae J, Brandwein J, Huebsch L, Beauregard-Zollinger L, Keating A.
    Exp Hematol; 1993 Mar 01; 21(3):405-410. PubMed ID: 8440338
    [Abstract] [Full Text] [Related]

  • 7. Short-term in vivo priming of bone marrow haematopoiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability.
    Hansen PB, Knudsen H, Gaarsdal E, Jensen L, Ralfkiaer E, Johnsen HE.
    Bone Marrow Transplant; 1995 Sep 01; 16(3):373-9. PubMed ID: 8535309
    [Abstract] [Full Text] [Related]

  • 8. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
    Sierra J, Terol MJ, Urbano-Ispizua A, Rovira M, Marin P, Carreras E, Batlle M, Rozman C.
    Exp Hematol; 1994 Jul 01; 22(7):566-72. PubMed ID: 8013572
    [Abstract] [Full Text] [Related]

  • 9. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
    Vose JM, Pandite AN, Beveridge RA, Geller RB, Schuster MW, Anderson JE, LeMaistre CF, Ahmed T, Granena A, Keating A, Fernandez Ranada JM, Stiff PJ, Tabbara I, Longo W, Copelan EA, Nichols C, Smith A, Topolsky DL, Bierman PJ, Lebsack ME, Lange M, Garrison L.
    J Clin Oncol; 1997 Apr 01; 15(4):1617-23. PubMed ID: 9193361
    [Abstract] [Full Text] [Related]

  • 10. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM, Rosti G, Visani G, Gherlinzoni F, Miggiano MC, Fortuna A, Zinzani P, Tura S.
    J Clin Oncol; 1996 Nov 01; 14(11):3018-25. PubMed ID: 8918500
    [Abstract] [Full Text] [Related]

  • 11. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec 01; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 12. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D, Miller J, Verfaillie C, Burns L, Wagner J, Blazar B, Davies S, Miller W, Hannan P, Steinbuch M, Ramsay N, McGlave P.
    Biol Blood Marrow Transplant; 1997 Oct 01; 3(4):217-23. PubMed ID: 9360784
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution.
    Calderwood S, Doyle JJ, Hitzler JK, Saunders EF, Freedman MH.
    Bone Marrow Transplant; 1996 Jul 01; 18(1):87-91. PubMed ID: 8832000
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Colony-stimulating activity in the serum of patients with hemopoietic malignancies after intensive chemotherapy/radiotherapy: its augmentation by GM-CSF in vivo and interleukin 4 in vitro.
    Millar BC, Bell JB, Millar JL, Treleaven J, Montes A, Joffe JK, Powles RL, McElwain TJ.
    Exp Hematol; 1992 Feb 01; 20(2):209-15. PubMed ID: 1371966
    [Abstract] [Full Text] [Related]

  • 17. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
    Elkordy M, Crump M, Vredenburgh JJ, Petros WP, Hussein A, Rubin P, Ross M, Gilbert C, Modlin C, Meisenberg B, Coniglio D, Rabinowitz J, Laughlin M, Kurtzberg J, Peters WP.
    Bone Marrow Transplant; 1997 Feb 01; 19(4):315-22. PubMed ID: 9051240
    [Abstract] [Full Text] [Related]

  • 18. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.
    Ippoliti C, Przepiorka D, Giralt S, Andersson BS, Wallerstein RO, Gutterman J, Deisseroth AB, Champlin RE.
    Bone Marrow Transplant; 1993 Jan 01; 11(1):55-9. PubMed ID: 8094309
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
    Vannucchi AM, Bosi A, Ieri A, Guidi S, Saccardi R, Lombardini L, Linari S, Laszlo D, Longo G, Rossi-Ferrini P.
    Bone Marrow Transplant; 1996 Apr 01; 17(4):527-31. PubMed ID: 8722349
    [Abstract] [Full Text] [Related]

  • 20. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.
    Clin Cancer Res; 1997 Sep 01; 3(9):1519-26. PubMed ID: 9815838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.